Adhera Therapeutics, Inc.
ATRX
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.79% | -34.08% | 35.77% | 77.83% | 136.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.79% | -34.08% | 35.77% | 77.83% | 136.03% |
| Operating Income | 50.79% | 34.08% | -35.77% | -77.83% | -136.03% |
| Income Before Tax | -96.06% | 173.74% | -1,097.30% | 79.93% | 51.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -96.06% | 173.74% | -1,097.30% | 79.93% | 51.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -96.06% | 173.74% | -1,097.30% | 79.93% | 51.77% |
| EBIT | 50.79% | 34.08% | -35.77% | -77.83% | -136.03% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -44.39% | 126.29% | 43.69% | 94.96% | 91.02% |
| Normalized Basic EPS | -37.49% | 169.62% | -216.52% | 94.27% | 89.07% |
| EPS Diluted | -44.78% | 94.70% | 43.69% | 94.96% | 91.02% |
| Normalized Diluted EPS | -37.49% | 102.46% | -216.52% | 94.27% | 89.07% |
| Average Basic Shares Outstanding | 36.16% | 203.70% | 269.85% | 269.76% | 386.82% |
| Average Diluted Shares Outstanding | 36.16% | 8,542.96% | 269.85% | 269.76% | 386.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
